CRSP vs LGND โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LGND Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ligand Pharmaceuticals Inc. (LGND) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CRSP counters with relative strength in Valuation. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus LGND at 25.8x Forward P/E and 14.4% operating margin (-31.8% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against LGND sits in CONSOLIDATION (8th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRSP Revenue | LGND Revenue | CRSP Op. Margin | LGND Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $250M | -5087.8% | 65.1% | LGND |
| FY2019 | $290M | $120M | 16.1% | 671.0% | LGND |
| FY2020 | $0M | $160M | -49295.5% | 22.9% | LGND |
| FY2021 | $910M | $240M | 40.8% | 43.0% | LGND |
| FY2022 | $0M | $200M | -56190.4% | 1.5% | LGND |
| FY2023 | $370M | $130M | -60.0% | 9.1% | LGND |
| FY2024 | $40M | $170M | -1250.4% | -13.5% | LGND |
| FY2025 | $0M | $270M | -18933.6% | 15.3% | LGND |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRSP | LGND | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.1B | $6.3B | Larger Scale | LGND |
| Trailing P/E Ratio Valuation | 23.4x | 127.0x | Lower Multiple | CRSP |
| Forward P/E Ratio Valuation | 23.4x | 25.8x | Lower Multiple | CRSP |
| Revenue Growth (YoY) Growth | +1325.1% | -31.8% | Higher Growth | CRSP |
| Operating Margin (TTM) Profitability | -2058.6% | 14.4% | Higher Margin | LGND |
| Net Profit Margin Profitability | 0.0% | 20.3% | Higher Margin | LGND |
| Return on Equity (ROE) Capital Efficiency | -25.6% | 5.4% | Higher ROE | LGND |
| 52-Week Range Position Momentum | 1% ($40โ$63) | 86% ($176โ$327) | Stronger Trend | LGND |
| Beta / 30D Volatility Risk Regime | 1.85ฮฒ ยท 60% Vol | 0.99ฮฒ ยท 38% Vol | Lower Realized Risk | LGND |
| Unified Institutional Score Composite Signal | 48.6 / 100 (HOLD) | 42.9 / 100 (HOLD) | Higher Composite | CRSP |